LOGO
LOGO

Can Agenus' New Strategies Pave The Way For A Strong Start In FY25?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Agenus Inc. (AGEN), a clinical-stage immuno-oncology company, on Thursday, announced financial and clinical strategies designed to prioritize its core programs while implementing significant cost-cutting measures.

As part of the strategic realignment, the company has planned to reduce cash burn to $100 million in 2025, following the successful closing of a $22 million mortgage secured by key real estate assets.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

RELATED NEWS
Latest Updates on COVID-19